Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05372003 · ClinicalTrials.gov registry record · Early Phase 1
IL-4 and Insulin Resistance for Treatment of Patients With Atopic Dermatitis
A Early Phase 1 study of Atopic Dermatitis, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT05372003 is a Early Phase 1 study of Atopic Dermatitis that has completed, run by Mayo Clinic. The registered enrollment target is 7 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05372003, a Early Phase 1 study of Atopic Dermatitis, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to better understand the interactions between the innate immune system, in particular eosinophils, their secreted cytokines (interleukin-4), and metabolism in human health and disease states such as obesity and insulin resistance.
Conditions Studied
Interventions
- DRUG Dupilumab
- OTHER Photo therapy
Study Locations (1)
Arizona
- Mayo Clinic Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2022-08-09 |
| Est. Completion | 2024-02-23 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05372003
The ClinicalTrials.gov registry entry for NCT05372003 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (99% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Dupilumab is the first listed.
NCT05372003 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT05372003 about?
NCT05372003 is a clinical study titled "IL-4 and Insulin Resistance for Treatment of Patients With Atopic Dermatitis". The purpose of this study is to better understand the interactions between the innate immune system, in particular eosinophils, their secreted cytokines (interleukin-4), and metabolism in human health and disease states such as obesity and insulin resistance.
What is the current status of trial NCT05372003?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2022-08-09. Estimated completion is 2024-02-23.
What conditions does trial NCT05372003 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT05372003?
The interventions under investigation include: Dupilumab (DRUG), Photo therapy (OTHER).
Who is sponsoring clinical trial NCT05372003?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05372003 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis
COMPLETED · Early Phase 1
-
Registry for Systemic Eczema Treatments
RECRUITING
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
RECRUITING
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
RECRUITING
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.